#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Primary adrenal insufficiency Cytomegalovirus infection Warm autoimmune haemolytic anaemia Demyelination Stress cardiomyopathy Vascular calcification Eosinophilic oesophagitis Familial amyotrophic lateral sclerosis Sarcoidosis Mantle cell lymphoma stage II Dent's disease Cholangitis sclerosing Thermal burn Cutaneous T-cell lymphoma refractory Paraganglion neoplasm More trials…

    Learn about Rare Diseases

    Atypical teratoid/rhabdoid tumour of CNS – Diagnostics Angelman’s syndrome – Diagnostics Systemic mastocytosis – Treatment Lysosomal storage disorder – Basic Information Glycogen storage disease type II – Trials in Disease Bronchopulmonary dysplasia – Treatment Haemolytic uraemic syndrome – Basic Information Waldenstrom’s macroglobulinaemia refractory – Life with Disease Vascular malformation – Diagnostics Primary biliary cholangitis – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Basimglurant Sunvozertinib Soft Paraffin And Fat Products Ibrexafungerp Medroxyprogesterone Acetate Murcidencel Tadalafil Avalglucosidase Alfa Resamirigene Bilparvovec CLESROVIMAB Nirmatrelvir Human Vaccinia Immunoglobulin Yttrium-90 Urapidil Riboflavin Sodium Phosphate Erenumab 177LU-PSMA-I&T Revumenib TEV-53408 Imgn151 More therapies…

    Learn about Your Condition

    Thymic carcinoma Schizophreniform disorder Immune-mediated renal disorder Mesothelioma Brain neoplasm malignant Pancoast's tumour Procedural headache Vulval cancer Diabetic retinopathy Chronic lymphocytic leukaemia Follicular lymphoma stage IV Anaemia of chronic disease Malignant mast cell neoplasm Hyperparathyroidism secondary Skin cancer More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

B-cell lymphoma refractory

  • Study of drug combination therapy in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma using odronextamab, loncastuximab tesirine and rituximab

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • B-cell lymphoma recurrent
    • B-cell lymphoma refractory
    Investigated Drugs:
    • Etoposide Phosphate
    • Loncastuximab Tesirine
    • Odronextamab
    Austria Belgium France The Netherlands Spain Sweden

  • Efficacy of KITE-753 Compared with Axicabtagene Ciloleucel in Adults with Relapsed or Refractory Large B‑Cell Lymphoma

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • B-cell lymphoma refractory
    Investigated Drugs:
    • Axicabtagene Ciloleucel
    Belgium Czechia France Germany Italy The Netherlands +2

  • A Study Testing the Safety of CD19-Targeted CAR T-Cell Therapy in Children and Young Adults with Relapsed or Refractory B-Cell Cancers

    Not yet recruiting

    1 1 1
    Investigated Diseases:
    • Acute lymphocytic leukaemia recurrent
    • B-cell lymphoma recurrent
    • B-cell lymphoma refractory
    Investigated Drugs:
    • MB-HUCART19.1
    The Netherlands

  • Study on the Safety and Effectiveness of Glofitamab and Obinutuzumab for Patients with Relapsed or Refractory B-cell Non-Hodgkin’s Lymphoma

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Glofitamab
    • Obinutuzumab
    • Tocilizumab
    Belgium Czechia Denmark Finland France Italy +2

  • Study on Tafasitamab with Gemcitabine, Oxaliplatin, and Rituximab for Patients with Aggressive B-cell Lymphoma

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Tafasitamab
    • Gemcitabine Hydrochloride
    • Oxaliplatin
    Germany

  • Study on the Safety and Tolerability of Epcoritamab with Drug Combination for Patients with B-cell Non-Hodgkin Lymphoma

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • Epcoritamab
    • Golcadomide
    • Ibrutinib
    Czechia Denmark France Germany Hungary The Netherlands +1
Previous Page
1 2 3
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!